FigureĀ 4.
Confirm the complete loss of core 1 O-glycans on GPIIb from A845/847 variant iPSC cell lines. (A) Schematic of local alloantigenic peptide and O-glycan modification of GPIIb from WT or HPA-3b A845/847 mutant cell lines. (B) Coimmunoprecipitation of GPIIb-IIIa complex with anti-GPIIIa monoclonal antibody AP3 from lysates of WT or HPA-3b A845/847-derived MKs, followed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblot with either PNA or rabbit anti-GPIIb polyclonal antibody. NeuAc, N-acetylneuraminic acid; Gal, galactose; GalNAc, N-acetyl-D-galactosamine; Co-IP, co-immunoprecipitation.

Confirm the complete loss of core 1 O-glycans on GPIIb from A845/847 variant iPSC cell lines. (A) Schematic of local alloantigenic peptide and O-glycan modification of GPIIb from WT or HPA-3b A845/847 mutant cell lines. (B) Coimmunoprecipitation of GPIIb-IIIa complex with anti-GPIIIa monoclonal antibody AP3 from lysates of WT or HPA-3b A845/847-derived MKs, followed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblot with either PNA or rabbit anti-GPIIb polyclonal antibody. NeuAc, N-acetylneuraminic acid; Gal, galactose; GalNAc, N-acetyl-D-galactosamine; Co-IP, co-immunoprecipitation.

Close Modal

or Create an Account

Close Modal
Close Modal